Comprehensive drug repurposing approach identifies Bavisant as a compound for regenerative therapeutics in multiple sclerosis
To assess the pro-myelinating and neuroprotective effects of the histamine H3 recepetor antagonist, we conducted bulk RNAseq on rat primary OPCs. Overall design: Comparative gene expression profiling and differentially regulated pathways analysis of RNA-seq data from rat primary OPCs cultures, in basal condition or after treatment with Bavisant at 1 µM and 10µM.